District sales manager, Novo Nordisk презентация

A world leader since 1923 A world leader since 1923 in diabetes care in insulin in injection devices Also leading positions in: Haemostasis Management Growth Hormone Therapy Hormone Replacement Therapy (HRT)

Novo Nordisk is a global healthcare company with 89 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Novo Nordisk is a global healthcare company with 89 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 32,500 employees in 75 countries, and markets its products in 190 countries. Novo Nordisk’s B shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO).

Employees by geographical area Employees by geographical area

Supplier of more than half of the world’s insulin Supplier of more than half of the world’s insulin The broadest range of pharmaceutical products and services The broadest portfolio of R&D diabetes projects The leader in insulin delivery systems Largest number of research projects Largest private research budget within diabetes

Every day, we must make difficult choices, always keeping in mind what is best for patients, our employees and our shareholders in the long run. Every day, we must make difficult choices, always keeping in mind what is best for patients, our employees and our shareholders in the long run. Our ambition is to strengthen our leadership in diabetes. Our key contribution is to discover and develop innovative biological medicines and make them accessible to patients throughout the world. We aspire to change possibilities in haemophilia and other serious chronic conditions where we can make a difference. Growing our business and delivering competitive financial results is what allows us to help patients live better lives, offer an attractive return to our shareholders and contribute to our communities. We never compromise on quality and business ethics. Our business philosophy is one of balancing financial, social and environmental considerations - we call it 'The Triple Bottom Line'. We are open and honest, ambitious and accountable and treat everyone with respect. We offer opportunities for our people to realise their potential. It's the Novo Nordisk Way.

The Essentials are ten statements describing what the Novo Nordisk Way looks like in practice. They are meant as a help to our managers and employees for evaluating to what extent our organisation acts in accordance with the Novo Nordisk Way. The Essentials are ten statements describing what the Novo Nordisk Way looks like in practice. They are meant as a help to our managers and employees for evaluating to what extent our organisation acts in accordance with the Novo Nordisk Way. We create value by having a patient-centred business approach. We set ambitious goals and strive for excellence. We are accountable for our financial, environmental and social performance. We provide innovation to the benefit of our stakeholders. We build and maintain good relations with our key stakeholders. We treat everyone with respect. We focus on personal performance and development. We have a healthy and engaging working environment. We optimise the way we work and strive for simplicity. We never compromise on quality and business ethics.

Independent, non-profit organisation founded in 2001 by Novo Nordisk. Independent, non-profit organisation founded in 2001 by Novo Nordisk. Supported by a grant from Novo Nordisk with a total maximum of 1.1 billion Danish kroner in the period 2001-2017, (195 million US dollars) Current project portfolio: 259.3 million dollars of which 85.8 million were donated by the World Diabetes Foundation. The World Diabetes Foundation is dedicated to supporting prevention and treatment of diabetes in the developing world through funding of sustainable projects. Funded 278 projects in 100 countries, currently focusing on access to diabetes prevention and care, awareness, education and capacity building at local, regional and global levels.

Product Supply

Local Manufacturing Kaluga Russia Introductory Slide Set [DATE]

1. Geography NN Headquarters located in Copenhagen, Denmark Travel time: Copenhagen <-> Kaluga

2. Project Purpose Russian Government to ensure “National Drug independence” 2008: import regulations intensified 2010: formal requirements for local manufacturing by 2014 Competition Sanofi-Aventis: packaging as of 2010, form.& fill. by 2012 Biosimilar domestic products

3. Project Scope 3 Processes are in scope: Formulation Filling – filling the drug into 20 mill. cartridges (Penfill®) + inspection Packaging – five pieces per package Additional: Packaging of 10 mill. FlexPen® The Kaluga facility will be operated by Product Supply Current reporting to Devices & Supply Chain Management Delivery to market First packaged PenFill® in Q3 2014 First filled PenFill® in Q2 2016

Visual Work Flow

3. Scope: Site Overview Production Plant

Scope: Site Overview Facility Support Areas